About Zinc finger protein 649
Zinc finger protein 649 (ZNF649) is a protein
from Homo sapiens identified by UniProt accession
Q9BS31, 505 residues long.
MolForge cross-references it against 0 known binders and
9 disease associations.
Target properties
| Protein name | Zinc finger protein 649 |
| UniProt accession | Q9BS31 |
| Gene | ZNF649 |
| Organism | Homo sapiens |
| Length | 505 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (9)
Diseases linked to this target (Open Targets).
- high density lipoprotein cholesterol measurement · score 0.04
- apolipoprotein A 1 measurement · score 0.03
- cognitive domain measurement · score 0.03
- neoplasm · score 0.01
- multiple sclerosis · score 0.00
- ulcerative colitis · score 0.00
- lung adenocarcinoma · score 0.00
- inflammatory bowel disease · score 0.00
- cancer · score 0.00
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q9BS31-F1 | alphafold | PREDICTED | 68.49 | — |
Amino-acid sequence (505 residues)
MTKAQESLTL EDVAVDFTWE EWQFLSPAQK DLYRDVMLEN YSNLVSVGYQ AGKPDALTKL EQGEPLWTLE DEIHSPAHPE IEKADDHLQQ PLQNQKILKR TGQRYEHGRT LKSYLGLTNQ SRRYNRKEPA EFNGDGAFLH DNHEQMPTEI EFPESRKPIS TKSQFLKHQQ THNIEKAHEC TDCGKAFLKK SQLTEHKRIH TGKKPHVCSL CGKAFYKKYR LTEHERAHRG EKPHGCSLCG KAFYKRYRLT EHERAHKGEK PYGCSECGKA FPRKSELTEH QRIHTGIKPH QCSECGRAFS RKSLLVVHQR THTGEKPHTC SECGKGFIQK GNLNIHQRTH TGEKPYGCID CGKAFSQKSC LVAHQRYHTG KTPFVCPECG QPCSQKSGLI RHQKIHSGEK PYKCSDCGKA FLTKTMLIVH HRTHTGERPY GCDECEKAYF YMSCLVKHKR IHSREKRGDS VKVENPSTAS HSLSPSEHVQ GKSPVNMVTV AMVAGQCEFA HILHS
Explore Zinc finger protein 649 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets